logo-loader
viewSkinBioTherapeutics PLC

SkinBioTherapeutics - Change of Adviser

RNS Number : 1484R
SkinBioTherapeutics PLC
26 June 2020
 

26 June 2020

 

SkinBioTherapeutics plc

 

Change of Adviser

 

SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, announces that Cenkos Securities plc has been appointed with immediate effect as the Company's Nominated Adviser and Sole Broker.

 

SkinBioTherapeutics plc

Tel: +44 (0) 161 468 2760

Stuart Ashman, CEO


Doug Quinn, CFO




Cenkos Securities plc (Nominated Adviser & Broker)

Tel: +44 (0)20 7397 8900

Giles Balleny, Max Gould (Corporate Finance)


Michael Johnson (Sales)

 


Instinctif Partners

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis

 [email protected]

 



About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.

The Company listed on AIM in April 2017 and is based in Manchester, UK.  For more information, visit: www.skinbiotherapeutics.com .  

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
APPBCGDLGXDDGGU

Quick facts: SkinBioTherapeutics PLC

Price: 24.8

Market: AIM
Market Cap: £31.76 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

SkinBioTherapeutics CEO hails 'significant scientific milestone' with...

SkinBioTherapeutics PLC's (LON:SBTX) CEO Stuart Ashman speaks to Proactive's Andrew Scott soon after updating investors on the progress of its cosmetic skincare programme and plans for a psoriasis food supplement trial. Sederma, its partner in the cosmetics programme and a division of Croda...

6 days, 22 hours ago